Lianbio
Officers & Directors
1. Bing Li: Chairman and CEO 2. Richard Li: Chief Scientific Officer 3. Xuesong Li: Chief Financial Officer 4. Michael Li: Executive Vice President and Head of Operations 5. Tom C. Chen: Vice President and Head of Corporate Development 6. Kevin Gong: Vice President and Head of Business Development 7. Kate Han: Vice President and Head of Human Resources 8. Joseph Xu: Vice President and Head of Legal and Compliance 9. Tina Chen: Vice President and Head of Communications and Investor Relations
Lianbio currently has 129 employees.
News about Lianbio Key Personnel |
In a recent press release, data management platform Komprise announced that it has experienced a significant boost in business, with a doubling of subscriptions in 2023. This growth can be attributed to both the increase in new customers as well as the expanded adoption of their unstructured data management platform. The surge in demand for their services highlights the growing recognition among enterprises of the importance of effectively managing unstructured data to unlock its potential for artificial intelligence (AI) applications.
The exponential growth in data generation by businesses has led to a rise in the volume of unstructured data. Unstructured data refers to the vast amount of data that...
|
LianBio Announces Resignation of CEO Yizhe Wang, Ph.D., Amidst Steady Growth in the Biotechnology Industry
SHANGHAI, China, and PRINCETON, N.J., Dec. 19, 2023 - LianBio (Nasdaq: LIAN), a leading biotechnology company committed to introducing groundbreaking treatments to patients in China and other significant Asian markets, has revealed that its Chief Executive Officer, Dr. Yizhe Wang, has resigned to explore new professional avenues. The announcement comes at a time when the company has showcased remarkable growth, with a year-on-year advancement of 1.35%.
Dr. Wang, a highly respected figure in the biotechnology field, has been instrumental in steering LianBio towards achieving its vision of revolu...
|
LianBio Rejects Acquisition Proposal from Concentra Biosciences, Focusing on Innovative Medicines for Asian Markets
Shanghai, China and Princeton, N.J. - LianBio (NASDAQ: LIAN), a leading biotechnology company committed to delivering groundbreaking medications to patients in China and other major Asian markets, has announced that its Board of Directors unanimously decided not to pursue the unsolicited proposal from Concentra Biosciences, LLC. The proposal entailed acquiring 100% of LianBio s equity for $4.30 per share in cash, accompanied by a contingent value right giving the acquirer 80% of the net proceeds from any license or disposition of LianBio s programs.
This resolute decision by LianBio s B...
|
In a recent development, LianBio, a lead...
|
|
